(19) World Intellectual Property Organization International Bureau



. HARRE BUINDER IN RESERVE BRANCH (1914 I 1914 BERNE BUINE BERNE BRANCH BERNE BUINDER BERNE BERNE BERNE BERNE

(43) International Publication Date 25 January 2001 (25.01.2001)

PCT

(10) International Publication Number WO 01/05970 A3

(51) International Patent Classification?: C12N 15/12, C07K 14/47, G01N 33/53, C12Q 1/68, A61K 38/17, C07K 16/18, A01K 67/027

(21) International Application Number: PCT/US00/19698

(22) International Filing Date: 19 July 2000 (19.07.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/144,595 19 July 1999 (19.07.1999) US 60/150,460 23 August 1999 (23.08.1999) US 60/159,849 15 October 1999 (15.10.1999) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US 60/144,595 (CIP)
Filed on 19 July 1999 (19.07.1999)
US 60/150,460 (CIP)
Filed on 23 August 1999 (23.08.1999)
US 60/159,849 (CIP)
Filed on 15 October 1999 (15.10.1999)

(71) Applicant (for all designated States except US): INCYTE GENOMICS, INC. [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Montain View, CA 94040 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). AU-YOUNG, Janice

[US/US]; 233 Golden Eagle Lane, Brisbane, CA 94005 (US). REDDY, Roopa [IN/US]; 1233 W. McKinley Avenue, #3, Sunnyvale, CA 94086 (US). YANG, Junming [CN/US]; 7125 Bark Lane, San Jose, CA 95129 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). LU, Dyung, Aina, M. [US/US]; 55 Park Belmont Place, San Jose, CA 95136 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US).

- (74) Agents: HAMLET-COX, Diana et al.; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).
- (81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

With international search report.

(88) Date of publication of the international search report: 26 April 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

/05970 A3

(54) Title: GTP-BINDING PROTEIN ASSOCIATED FACTORS

(57) Abstract: The invention provides human GTP-binding associated proteins (GBAP) and polynucleotides which identify and encode GBAP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of GBAP.

Interr nal Application No PCT/US 00/19698

a. classification of subject matter IPC 7 C12N15/12 C07K14/47 G01N33/53 C12Q1/68 A61K38/17 C07K16/18 A01K67/027 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED $\begin{array}{lll} \mbox{Minimum documentation searched} & \mbox{(classification system followed by classification symbols)} \\ \mbox{IPC 7} & \mbox{C12N} & \mbox{C07K} & \mbox{G01N} & \mbox{C12Q} & \mbox{A61K} & \mbox{A01K} \\ \end{array}$ Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) **STRAND** C. DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Category ' Citation of document, with indication, where appropriate, of the relevant passages 11-15 DATABASE EMEST HUM1 [Online] Х Entry/Acc.no. AA679577, 4 December 1997 (1997-12-04)
HILLIER, L. ET AL.: "zj49c09.s1 Soares
fetal liver spleen 1NFLS S1 Homo sapiens
cDNA clone 453616 3' similar to
TR:G1230663 G1230663 SIMILAR TO E. COLI HYPOTHETICAL 22.1 KD PROTEIN IN POLA 3' REGION." XP002148938 the whole document -/--Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents : "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention "E" earlier document but published on or after the international filing date "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report U1 n 8. 01. 2 October 2000 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Smalt, R

2

Inter nal Application No
PCT/US 00/19698

	PC1/02 00/19698						
C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Category © Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.							
Citation of document, with indication, where appropriate, of the relevant passages	nelevant to claim No.						
DATABASE EMBL - EMEST HUM13 [Online] Entry HS1229641, Acc.no. AA429983, 25 May 1997 (1997-05-25) HILLIER, L. ET AL.: "zw60f01.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA cTone IMAGE:774457 5" similar to SW:YSXC BACSU P38424 HYPOTHETICAL 22.0 KD PROTEIN IN LON-HEMA INTERGENIC REGION; mRNA sequence." XP002148939 the whole document	11-15						
DATABASE EMBL - EMEST ROD2 [Online] Entry/Acc.no. AI122094, 8 September 1998 (1998-09-08) MARRA, M. ET AL.: "uc46f10.r1 Soares mouse mammary gland NMLMG Mus musculus cDNA clone IMAGE:1401067 5' similar to SW:Y335 MYCGE P47577 HYPOTHETICAL GTP-BINDING PROTEIN MG335.;, mRNA sequence." XP002148940 the whole document							
DATABASE EMBL - EMHUM2 [Online] Entry/Acc.no. AF161484, 1 February 2000 (2000-02-01) YE, M. ET AL.: "Homo sapiens HSPC135 mRNA, complete cds." XP002148941 the whole document	1,3,6-9, 11-16, 20,23						
WO 99 58675 A (CHIRON CORP ;HYSEQ INC (US)) 18 November 1999 (1999-11-18) the whole document	11-15						
CLAPHAM, D.E. ET AL.: "New roles for G-protein beta-gamma-dimers in transmembrane signalling." NATURE, vol. 365, 30 September 1993 (1993-09-30), pages 403-6, XP002148967 cited in the application the whole document							
	DATABASE EMBL - EMEST_HUM13 [Online] Entry HS1229641, Acc.no. AA429983, 25 May 1997 (1997-05-25) HILLIER, L. ET AL.: "zw60f01.rl Soares total fetus Nb2HF8 9w Homo sapiens cDNA cTone IMAGE:774457 5T similar to SW:YSXC BACSU P38424 HYPOTHETICAL 22.0 KD PROTEIN IN LON-HEMA INTERGENIC REGION; mRNA sequence." XP002148939 the whole document DATABASE EMBL - EMEST ROD2 [Online] Entry/Acc.no. AI122094, 8 September 1998 (1998-09-08) MARRA, M. ET AL.: "uc46f10.rl Soares mouse mammary gland NMLMG Mus musculus cDNA clone IMAGE:1401067 5' similar to SW:Y335 MYCGE P47577 HYPOTHETICAL GTP-BINDING PROTEIN MG335. ;, mRNA sequence." XP002148940 the whole document DATABASE EMBL - EMHUM2 [Online] Entry/Acc.no. AF161484, 1 February 2000 (2000-02-01) YE, M. ET AL.: "Homo sapiens HSPC135 mRNA, complete cds." XP002148941 the whole document WO 99 58675 A (CHIRON CORP; HYSEQ INC (US)) 18 November 1999 (1999-11-18) the whole document CLAPHAM, D.E. ET AL.: "New roles for G-protein beta-gamma-dimers in transmembrane signalling." NATURE, vol. 365, 30 September 1993 (1993-09-30), pages 403-6, XP002148967 cited in the application						

2

ational application No. PCT/US 00/19698

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Although claims 18, 21 and 24 are directed to a method of treatment of the
	human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. X	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: see FURTHER INFORMATION sheet PCT/ISA/210
з. 🗌	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This inte	ernational Searching Authority found multiple inventions in this international application, as follows:
	see additional sheet
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. X	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-28 all partially
Remar	k on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

Invention 1: Claims 1-28, all partially

A protein with at least 90% identity to seq.ID.1 or biologically active or immunogenic fragment thereof, polynucleotide encoding it, optionally transcriptionally linked to a promoter, cell transformed therewith, transgenic organism comprising said polynucleotide, method for producing said protein using said cell, antibody against said protein, polynucleotides having at least 70% sequence homology to seq.ID.67 of at least 60 nt, method for detecting said nucleic acid by hybridization with a probe of at least 20 nt or by amplification, pharmaceutical composition of the protein, methods for screening for (ant)agonists of the protein or modulators of the proteins expression or activity and compounds identified thereby.

Inventions 2-61: claims 1-28, all partially

Subject matter as defined above under invention 1, but limited to the respective protein/nucleic acid sequences:

- 2 and 68, 3 and 69,
- 4. 4 and 70,
- 5. 5 and 71,
- 6 and 72,
- 7 and 73,
- 8 and 74, 9. 9 and 75,
- 10.10 and 76,
- 11.11 and 77,
- 12.12 and 78,
- 13.13 and 79,
- 14.14 and 80,
- 15.15 and 81,
- 16.16 and 82,
- 17.17 and 83.
- 18.18 and 84,
- 19.19 and 85,
- 20.20 and 86,
- 21.21 and 87, 22.22 and 88,
- 23.24 and 90,
- 24.25 and 91,
- 25.26 and 92,
- 26.27 and 93.
- 27.29 and 95. 28.30 and 96,
- 29.31 and 97,
- 30.32 and 98, 31.33 and 99,
- 32.34 and 100,

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210 33.36 and 102, 34.37 and 103, 35.38 and 104, 36.39 and 105, 37.40 and 106, 38.41 and 107, 39.43 and 109, 40.44 and 110, 41.45 and 111, 42.46 and 112, 43.47 and 113, 44.48 and 114, 45.49 and 115, 46.50 and 116, 47.52 and 118, 48.53 and 119, 49.54 and 120, 50.55 and 121, 51.56 and 122, 52.57 and 123, 53.58 and 124, 54.59 and 125, 55.60 and 126, 56.61 and 127, 57.62 and 128, 58.63 and 129, 59.64 and 130, 60.65 and 131, and 61.66 and 132. For the sake of conciseness, the first subject matter is explicitly defined, the other subject matters are defined by analogy thereto.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claim 12 of the underlying application relates to a polynucleotide comprising at least 60 nt of a polynucleotide, which has at least 70% sequence identity to a nucleic acid sequence selected from those listed in claim 5. Since the at least 60 nucleotides need not originate from an area of homology with any of the sequences of claim 5, the polynucleotide claimed in claim 12 is not defined in any way. The search of said claim has been limited to nucleic acids comprising a nucleic acid sequence having at least 70% homology to a nucleic acid sequence selected from claim 5 of at least 60 nt in length.

Present claims 20 and 23 refer to agonists and antagonists, respectively, defined by reference to a desirable characteristic or property, namely the fact that they can be obtained by certain screening methods. The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to proteins with at least 90% homology to seq.ID.1 and antibodies thereto.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

..iormation on patent family members

Interr nal Application No
PCT/US 00/19698

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9958675	A	18-11-1999	AU AU EP	4187499 A 2095599 A 1053319 A	29-11-1999 19-07-1999 22-11-2000
			WO WO	9933982 A 9938972 A	08-07-1999 05-08-1999
			AU WO	6263999 A 0018916 A	17-04-2000 06-04-2000